title: [Changes of somatostatin receptor of pancreas and effectiveness of octreotide on acute necrotizng pancreatitis in mice].
abstract: OBJECTIVE
  Changes of somamtostatin receptor (SSTR) of pancreas, pancreatic blood flow and its relationship to metabolism of eicosanoids were investigated in order to elucidate the effectiveness of octreotide, an analogue of somatostatin, in acute necrotizng pancreatitis (ANP).
  
  
  METHODS
  Rats with ANP were triggered with sodium taurocholate via pancreatobillary duct; SSTR was detected by radioligand binding assay (RBA) with (125)I-somatostatiin-14; in Situ hybridization was employed in analysis of SSTR2 mRNA of pancreas; pancreatic blood flow was determined with tissue blood flowmeter and metabolites of eicosanoids were analyzed with radioimmunoassay.
  
  
  RESULTS
  The level of SSTR of pancreas was 110 +/- 58 fmol/mg.protein in normal rats. Significant decrease of SSTR was shown at 3, 6, 12 hours after onset of ANP and of the signals of SSTR2 mRNA by in situ hybridization as well. Pancreatic blood flow was reduced while thromboxin-2 was increased significantly in the course of ANP. But in the group of ANP treated with octreotide, both the decrease of pancreatic blood flow and abnormal metabolism of eicosanoids were corrected, and the pathologic damages were reduced.
  
  
  CONCLUSIONS
  SSTR of pancreas is significantly reduced in ANP. Therefore, correction of abnormal metabolism of eicosanoids and improvement of pancreatic microcirculation may be the major mechanism of somatostatin analogues in treatment of ANP while inhibition of pancreatic enzymes via receptors may play a minor role.
authors.affiliation: Department of Gastroenterology, Shanghai First People's Hospital, Shanghai 200080, China.
authors.forename: J
authors.initials: J
authors.lastname: Wu
authors.forename: Y
authors.initials: Y
authors.lastname: Yuan
authors.forename: J
authors.initials: J
authors.lastname: Xu
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017481:Receptors, Somatostatin / Q000378:metabolism*
chemical_list: D005765:Gastrointestinal Agents; D017481:Receptors, Somatostatin; D015282:Octreotide